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The osteogenic potential of mesenchymal stromal cells (MSCs) varies among different tissue sources. Strontium enhances the
osteogenic differentiation of bone marrow-derived MSCs (BM-MSCs), but whether it exerts similar effects on placental decidual
basalis-derived MSCs (PDB-MSCs) remains unknown. Here, we compared the influence of strontium on the proliferation and
osteogenic differentiation of human PDB- and BM-MSCs in vitro. We found that 1mM and 10mM strontium, but not 0.1mM
strontium, evidently promoted the proliferation of human PDB- and BM-MSCs. These doses of strontium showed a comparable
alkaline phosphatase activity in both cell types, but their osteogenic gene expressions were promoted in a dose-dependent
manner. Strontium at doses of 0.1mM and 1mM elevated several osteogenic gene expressions of PDB-MSCs, but not those of
BM-MSCs at an early stage. Nevertheless, they failed to enhance the mineralization of either cell type. By contrast, 10mM
strontium facilitated the osteogenic gene expression as well as the mineralization of human PDB- and BM-MSCs. Collectively,
this study demonstrated that human PDB- and BM-MSCs shared a great similarity in response to strontium, which promoted
their proliferation and osteogenic differentiation in a dose-dependent manner.
1. Introduction
Large bone defects, resulting from trauma, infection, and
congenital diseases, remain a great challenge in the
clinic. Mesenchymal stromal cells (MSCs) are fibroblast-
like adherent cells with a self-renewal ability and multipo-
tency. They are considered as promising seed cells for bone
regeneration, mainly due to their osteogenic potential and
paracrine effects [1, 2]. Currently, bone marrow represents
the main source of MSCs for clinical studies. A great
number of animal studies and several clinical trials have
shown that bone marrow-derived MSCs (BM-MSCs)
improved bone regeneration [2, 3]. However, several draw-
backs hinder wide clinical application. For example, the iso-
lation of BM-MSCs requires an invasive procedure, and the
proliferation and differentiation capability of BM-MSCs
decrease with donor age [4, 5]. Therefore, many researches
tried to explore other sources of MSCs for bone regeneration.
The human placenta is an attractive source of MSCs
because of the noninvasive tissue collection, the lack of
ethical concerns, the high cell harvest rate, and the robust cell
proliferation ability [6]. MSCs have been isolated from
different parts of the placenta, including the chorionic villi,
amnion membrane, and decidual basalis [7–10]. They can
undergo osteogenic differentiation when cultured in the tra-
ditional osteogenic medium or stimulated by the osteogenic
growth factors (e.g., bone morphogenic proteins) in vitro
[11]. When grafted in combination with osteoinductive
scaffolds, they are able to form bone tissue at the ectopic sites
[12, 13]. Noticeably, they also enhanced bone regeneration
after transplantation at the bone defects [14, 15]. Neverthe-
less, several studies have revealed that the osteogenic poten-
tial of placenta-derived MSCs was inferior to that of the
BM-MSCs [16–18], highlighting the need of developing
efficient strategies to improve the osteogenic commitment
of cells.
Strontium is a trace element in natural bone tissue that
has dual effects on bone metabolism. It enhances the prolifer-
ation of osteoprogenitor cells, while inhibiting the terminal
differentiation of osteoclasts [19]. Considering the chemical
stability and low cost of strontium, many efforts have been
made in developing strontium-modified scaffolds to enhance
bone repair in combination with MSCs [20, 21]. It is well-
known that strontium promotes the osteogenic differentia-
tion of osteoblast and BM-MSCs derived from rodent species
[22–28]. However, much fewer studies have determined the
effect of strontium on MSCs derived from human tissues
[29–32], especially those derived from perinatal tissues. Yang
et al. has reported the enhanced osteogenic response of
human umbilical cord-derived MSCs to strontium stimula-
tion [32], but the influence of strontium on MSCs derived
from other human perinatal tissues, such as the decidual
basalis, has not been investigated yet.
Since tissue origin profoundly influences the biological
properties of MSCs, including their proliferation ability and
differentiation potential [16–18, 33], it is reasonable to
assume that human BM-MSCs and placental decidual
basalis-derived MSCs (PDB-MSCs) might respond differ-
ently to strontium stimulation. In this study, we first deter-
mined the proper treatment doses of strontium for both cell
types and then compared the effect of strontium on their
osteogenic differentiation in vitro, with the aim of providing
valuable information for potential applications of strontium
for MSC-based bone regeneration.
2. Materials and Methods
2.1. Cell Isolation. This study was approved by the ethics
committee of West China Hospital, Sichuan University.
Human placentas were obtained from four healthy donors
(age ranging from 25 to 33) with informed consent. PDB-
MSCs were isolated as described in our previous report [7].
Briefly, decidua basalis was dissected from placentas, washed
in phosphate-buffered saline (PBS), minced into small pieces
of tissue, and digested with 0.25% Trypsin (Gibco, USA) and
0.1% Collagenase IV (Invitrogen, USA). After centrifugation,
the nucleated cells were resuspended and cultured in the
growth medium containing Dulbecco’s modified Eagle’s
medium-high glucose (Gibco, USA), 10% fetal bovine serum
(HyClone, USA), and 1% penicillin/streptomycin (Gibco,
USA). The growth medium was changed every 3 days. When
the cells reached 70-80% confluence, they were collected by
0.25% trypsin/ethylene diamine tetraacetic acid (EDTA;
Sigma-Aldrich, USA) treatment and passaged at a dilution
of 1 : 3. Cells from the 4th passage of each donor were pooled
together, and the mixed cells were cultured for an additional
1 to 3 passages for further use in the subsequent studies.
Human bone marrow samples were obtained from one
healthy female donor (25 years old) and three patients with
scoliosis (one female donor and two male donors, age
ranging from 15 to 18) with informed consent. BM-MSCs
were isolated according to our previous description [34].
Briefly, bone marrow aspirates were diluted with PBS, layered
over Ficoll solution (TBD Science, China), and centrifuged at
500 g for 30mins to collect mononuclear cells from the
gradient interface. Then, the mononuclear cells were cultured
in the growth medium, which was changed to remove the
nonadherent cells after 72 hours of culture. When the cells
reached 70-80% confluence, they were passaged at a ratio of
1 : 3. The cells at passage 4 from each donor were pooled
together, and the mixed cells were subcultured for additional
passages. Cells at the 5th to 7th passage were used in the
following experiments.
2.2. Cell Characterization. The multilineage differentiation
potential of human BM-MSCs and PDB-MSCs was investi-
gated according to our previous reports [7, 34]. Briefly, the
cells were seeded at a density of 1 × 104 cells/cm2. For osteo-
genic differentiation, the cells were cultured in the osteogenic
medium containing the growth medium, 50mg/L L-ascorbic
acid-2-phosphate (Sigma-Aldrich, USA), 10-7M dexametha-
sone (Sigma-Aldrich, USA), and 10mM β-glycerophosphate
(Sigma-Aldrich, USA). The osteogenic medium was changed
every 3 days. After induction for 21 days, the samples
were fixed in 75% ethanol and stained with 1% alizarin
red solution (Sigma-Aldrich, USA) for 30mins at 37°C.
For adipogenic differentiation, the cells were cultured in
the adipogenic medium containing the growth medium,
0.25μM dexamethasone (Sigma-Aldrich, USA), 10μM insu-
lin (Sigma-Aldrich, USA), 0.5μM isobutyl-methylxanthine
(Sigma-Aldrich, USA), and 50μM indomethacin (Sigma-
Aldrich, USA). The adipogenic medium was changed every
3 days. After induction for 15 days, the samples were fixed
with 10% formalin and stained with oil red O solution
(Sigma-Aldrich, USA) for 45mins to detect lipid droplets in
the cytoplasm.
For chondrogenic differentiation, the cells were cul-
tured in the chondrogenic medium containing the growth
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medium, 100mg/L sodium pyruvate (Sigma-Aldrich, USA),
10μg/L transforming growth factor-β1 (R&D Systems,
USA), 100mg/L ascorbate-2-phosphate (Sigma-Aldrich,
USA), 1% insulin-transferrin-selenium (Gibco, USA), and
0.1μMdexamethasone (Sigma-Aldrich, USA). The chondro-
genic medium was changed every 3 days. After induction for
14 days, the samples were stained with Alcian Blue 8GX
(Cyagen Biosciences, China) for 30mins to observe the depo-
sition of glycosaminoglycans. After histological staining, all
of the samples were observed and photographed by a
phase-contrast microscope (Olympus Corporation, Japan).
2.3. Cell Proliferation. Both BM- and PDB-MSCs were
cultured in the growth medium or the growth medium
supplemented with different concentrations of SrCl2·6H2O
(Kelong, China), respectively. The cells cultured in the
growth medium served as the control group. Briefly, the cells
were seeded at a density of 3000 cells/well in 96-well plates.
Cell proliferation was continually monitored using an ala-
marBlue® Cell Viability Reagent (Invitrogen, USA) on days
1, 3, and 7. At each timepoint, the cells were rinsed with
PBS and then incubated with 100μL working solution
prepared according to the manufacturer’s instructions for
4 h at 37°C. Finally, the absorbance was recorded using a
plate reader (Molecular Devices, USA) at 570nm, using
600nm as a reference wavelength.
2.4. Live/Dead Staining. Human BM-MSCs were seeded at a
density of 5,000 cells/cm2 in 12-well plates and cultured in
the growth medium or the growth medium supplemented
with strontium at doses of 0.1mM, 1mM, and 10mM,
respectively. On days 1, 3, and 7, a Live/Dead® Cell Viability
Assay Kit (Invitrogen, USA) was used to monitor cell via-
bility. The samples (n = 3 for each group) were gently
washed with PBS for two times and then incubated in
the working solution for 30mins at 37°C. Cell viability
was observed by an inverted fluorescence microscope
(Olympus Corporation, Japan).
2.5. Cell Apoptosis Analysis. Human BM-MSCs were seeded
at a density of 5,000 cells/cm2 in 25 cm2 culture flasks and
cultured in the growth medium or the growth medium
supplemented with different doses of strontium (0.1mM,
1mM, and 10mM) for 3 days, respectively. The cells cultured
in the growth medium served as the control group. After cell
culture, the cells were harvested for apoptosis detection
(Annexin V-FITC Apoptosis Detection Kit, Beyotime
Institute of Biotechnology, China) according to the manufac-
turer’s instructions, and the samples were analysed using
flow cytometry (FACSAria II, BD Biosciences, USA).
2.6. Alkaline Phosphatase (ALP) Activity Assay. Human BM-
and PDB-MSCs were seeded at a density of 5000 cells/cm2
and cultured in the growth medium or the osteogenic
medium added with different doses of strontium (0.1mM,
1mM, and 10mM), respectively. The cells cultured in the
growth medium or the osteogenic medium served as the con-
trol group, respectively. After 7 days of culture, the ALP
activity of cells (n = 4 for each group) was measured using
an ALP assay kit (Nanjin Jiancheng Bioengineering Institute,
China). Briefly, the cells were detached by 0.25% trypsin/
EDTA, resuspended in deionized H2O (100μL/sample),
and lysed by three freeze-thaw cycles. Then, the ALP activity
of cell lysates was determined according to the manufac-
turer’s instructions. The absorbance at 405nm was read by
a plate reader (Molecular Devices, USA). The ALP activity
results were normalized to the amount of total protein, which
was quantified using a BCA protein assay kit (Bio-Rad, USA).
2.7. ALP Staining. Human BM- and PDB-MSCs were seeded
at a density of 5000 cells/cm2 and cultured with different
doses of strontium (0.1mM, 1mM, and 10mM) supple-
mented in the growth medium or the osteogenic medium,
respectively. The cells cultured in the growth medium or
the osteogenic medium served as the control group, respec-
tively. After 7 days of culture, the ALP activity of cells
(n = 3 for each group) was observed using an ALP staining
kit (Sigma-Aldrich, USA). Briefly, the cells were fixed in 4%
phosphate-buffered paraformaldehyde for 30mins at room
temperature, washed with running water, stained with an
ALP staining kit according to the manufacturer’s instruc-
tions, and finally observed using microscopy (Olympus
Corporation, Japan).
2.8. Real-Time Polymerase Chain Reaction (RT-PCR). Human
BM- and PDB-MSCs were seeded at a density of 5000
cells/cm2 and cultured with different doses of SrCl2·6H2O
(0.1mM, 1mM, and 10mM) supplemented in the growth
medium or the osteogenic medium, respectively. The cells
cultured in the growth medium or the osteogenic medium
served as the control group, respectively. After culture for
3, 7, and 14 days, total RNA (n = 4 for each group) was
extracted using a RNAiso Plus reagent (Takara Bio, Japan)
and then reverse-transcribed into cDNA using a Prime-
Script RT Reagent Kit (Takara Bio, Japan). Gene expression
was quantified using a SYBR Premix Ex Taq II Kit (Takara
Bio, Japan) in an iQ5 real-time system (Bio-Rad, USA).
The primers for the osteogenic genes and the housekeep-
ing gene, including runt-related transcription factor 2
(Runx2), osteocalcin (OC), osteoprotegerin (OPG), osteo-
pontin (OPN), and glyceraldehyde-3-phosphate dehydroge-




TCCTGAAAGCCGATGTGGTC; OPN: forward primer—
TGACCAGAGTGCTGAAACCCA, reverse primer—CCTG
ACTATCAATCACATCGGAAT; OPG: forward primer—
GGTCTCCTGCTAACTCAGAAAGG, reverse primer—
CAGCAAACCTGAAGAATGCCTCC; and GAPDH: forward
primer—CTTTGGTATCGTGGAAGGACTC, reverse primer—
GTAGAGGCAGGGATGATGTTCT. GADPH served as the
housekeeping gene. Target gene expression was analyzed
by the 2-△△Ct method. Results were expressed relative to
the gene expression level of the control group.
2.9. Mineralization Assay. Human BM- and PDB-MSCs
were seeded at a density of 5000 cells/cm2 in 6-well plates
and were cultured in the osteogenic medium supplemented
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with different doses of strontium (0.1mM, 1mM, and
10mM) for 21 days, respectively. The cells cultured in the
osteogenic medium served as the control group. After induc-
tion, the samples (n = 3 for each group) were stained with
alizarin red as described above and were grossly visualized.
2.10. Statistical Analysis. Data were expressed as the mean ±
standard deviation (SD). A one-way ANOVA followed by
Dennett’s Multiple Comparison Test was performed for sta-
tistical testing using GraphPad Prism software (GraphPad
Software Inc., USA), and p < 0:05 was considered significant.
3. Results
3.1. Strontium Enhanced the Proliferation of BM- and PDB-
MSCs. Human BM- and PDB-MSCs were characterized
before investigating their responses to strontium stimulation.
Similar to our previous reports [7, 34], both cells showed
a fibroblastic-like morphology and possessed the osteo-
genic, adipogenic, and chondrogenic differentiation potential
in vitro (Figure 1). Interestingly, after chondrogenic induc-
tion, both BM- and PDB-MSCs were positive for Alcian blue
staining, but there was an obvious difference between them: a
multilayered cell sheet was observed in BM-MSCs, while
PDB-MSCs formed cellular nodules. This result indicates a
tissue origin-dependent variation in the chondrogenic poten-
tial of MSCs, which has been reported by other research
groups [35].
To determine the proper doses of strontium, both cell
types were cultured with different concentrations of stron-
tium (0.01mM, 0.1mM, 0.5mM, 1mM, 5mM, 10mM, and
20mM). The cell proliferation was evaluated on days 1, 3,
and 7. As shown in Figure 2(a), strontium, at doses of
0.01mM, 0.5mM, 1mM, 5mM, and 10mM, facilitated the
growth of BM-MSCs, while 20mM strontium inhibited the
replication. For PDB-MSCs, the growth rate of cells treated
with 0.01mM, 0.1mM, and 0.5mM strontium was compara-
ble to the GM group at all timepoints. 1mM, 5mM, and
10mM strontium promoted the proliferation of PDB-MSCs
on day 7, while 20mM strontium showed an evident
inhibition on days 3 and 7 (Figure 2(b)).
To further confirm the cytotoxic effects of strontium on
human BM-MSCs, live/dead staining and cell apoptosis
analysis were performed. As shown in Figure 3(a), the cells
showed good viability (green fluorescence) on days 1, 3,
and 7, and few dead cells (red fluorescence) were observed
in each group. Similarly, the result of an apoptosis assay
revealed a comparable cell viability in the 0.1mM, 1mM,
and 10mM strontium groups when comparing with the
GM group (Figure 3(b)).
Considering the fact that the average strontium concen-
tration in the serum of postmenopausal women taking
2 g/day strontium ranelate orally is 0.117mM [36], and
combining this information with the above results, we
therefore chose 0.1mM, 1mM, and 10mM strontium in
the subsequent experiments to investigate the osteogenic
effects of strontium on BM- and PDB-MSCs.
3.2. Strontium Promoted the Osteogenic Differentiation of
BM- and PDB-MSCs in the Growth Medium. To determine
whether strontium promoted the osteogenic differentiation
of human BM- and PDB-MSCs without any other soluble
osteogenic factors, both cells were cultured in the growth
medium supplemented with different doses of strontium.
Then, the osteogenic differentiation of cells was measured,
including the ALP activity and the osteogenic gene
expression.
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 1: Characterization of human BM- and PDB-MSCs. Morphology of (a) BM-MSCs and (e) PDB-MSCs; scale bar: 200 μm. Alizarin red
staining of (b) BM-MSCs and (f) PDB-MSCs after osteogenic induction; scale bar: 200 μm. Oil red O staining of (c) BM-MSCs and (g) PDB-
MSCs after adipogenic induction; scale bar: 200μm. Alcian blue staining of (d) BM-MSCs and (h) PDB-MSCs after chondrogenic induction;
scale bar: 200μm for (d) and 100 μm for (h).













































































































































































































Figure 2: Proliferation of BM- and PDB-MSCs cultured with different doses of strontium supplemented in the growth medium. (a) BM-
MSCs. (b) PDB-MSCs. ∗P < 0:05 when compared with the GM group; #P < 0:01 when compared with the GM group. GM: growth
medium. All of these results are representative of three independent experiments.
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Figure 3: Cytotoxic effects of strontium on human BM-MSCs. (a) Live/dead staining of human BM-MSCs cultured with different
concentrations of strontium; green fluorescence: live cells; red fluorescence: dead cells; scale bar: 500 μm. (b) Cell apoptosis analysis of
human BM-MSCs. The percentages of the following cell populations are indicated on the respective density plots: necrotic cells (Annexin
V-negative and PI-positive) are located in the upper left (C1), late apoptotic cells (Annexin V-positive and PI-positive) in the upper right
(C2), viable cells (Annexin V-negative and PI-negative) in the lower left (C3), and early apoptotic cells (Annexin V-positive and PI-
negative) in the lower right (C4) quadrants, respectively. GM: growth medium. All of these results are representative of three
independent experiments.
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As shown in Figure 4(a), only a few cells were positive for
the ALP staining in both cell types after 7 days of culture, and
there was no obvious difference among all groups in each cell
type. Accordingly, the ALP activity of strontium groups
(0.1mM, 1mM, and 10mM) was comparable to that of the
GM group (P > 0:05, Figure 4(b)). However, when compar-
ing with the ALP staining of BM-MSCs, a much weaker
staining result was found after PDB-MSCs were treated with
the same concentration of strontium (Figure 4(a)).
The osteogenic gene expression of cells on days 3, 7, and
14, including the expression of Runx2,OC,OPN, andOPG, is
shown in Figure 4(c). For BM-MSCs, 0.1mM and 1mM
strontium demonstrated a similar gene expression level when
compared with the GM group, while 10mM strontium sig-
nificantly enhanced the expression of OC, OPN, and OPG
on days 3, 7, and 14, and the expression of Runx2 on day 3.
For PDB-MSCs, 0.1mM and 1mM strontium elevated the
expression of Runx2 on day 3, as well as the expression of
OC on day 7. Furthermore, 10mM strontium enhanced the
expression of OPN and OPG on day 14.
Altogether, these results revealed that, even without
any other soluble osteogenic factors, strontium promoted
the osteogenic differentiation of both cells in a dose-
dependent manner.
3.3. Strontium Promoted the Osteogenic Differentiation of
BM- and PDB-MSCs in the Osteogenic Medium. We next
determined whether strontium enhanced the osteogenic
differentiation of BM- and PDB-MSCs in an osteogenic
microenvironment in vitro. Both cells were cultured in the
osteogenic medium supplemented with different doses of
strontium. The osteogenic differentiation of cells was
measured by the ALP activity on day 7, the expression of
osteogenic genes on days 3, 7, and 14, and finally the miner-
alization of extracellular matrix on day 21.
As shown in Figure 5(a), both cells were positive for ALP
staining after osteogenic induction, but there was no obvious
difference among all groups in each cell type. Similarly, ALP
activity of the strontium groups (0.1mM, 1mM, and 10mM)
was comparable to that of the osteogenic medium (OST)
group on day 7 (P > 0:05, Figure 5(b)). Interestingly, BM-
MSCs showed stronger staining results when comparing with
that of PDB-MSCs after treated with the same concentration
of strontium (Figure 5(a)).
As shown in Figure 5(c), strontium promoted the
osteogenic gene expression of both cell types in a dose-
dependent manner. For BM-MSCs, 0.1mM and 1mM
strontium showed a comparable osteogenic gene expression
level to that of the OST group, while 10mM strontium
enhanced the expression of Runx2 on day 7, the expression
of OC on days 3, 7, and 14, the expression of OPN on days
3 and 7, and the expression of OPG on days 7 and 14.
For PDB-MSCs, 0.1mM strontium elevated the expres-
sion of OPN on days 7 and 14; 1mM strontium enhanced
the expression of OC on day 7; and notably, 10mM stron-
tium enhanced more osteogenic gene expressions than the
0.1mM and 1mM groups, facilitating the expression of OC
on days 7 and 14, the expression of OPN on day 7, and the
expression of OPG on days 3, 7, and 14 (Figure 5(c)).
The mineralization of cells was observed by the Alizarin
red staining (Figure 5(d)). Compared with the OST group,
0.1mM and 1mM strontium showed a similar mineraliza-
tion in both cell types, while 10mM strontium obviously
enhanced their mineralization.
Taken together, the above results clearly demonstrated
that strontium can effectively promote the osteogenic differ-
entiation of both BM- and PDB-MSCs under traditional
osteogenic induction in vitro.
4. Discussion
PDB-MSCs are multipotent and readily available and, thus,
present a potential cell source for bone repair. Nevertheless,
the osteogenic potential of MSCs derived from the placenta
tissues has been shown to be inferior to that of BM-MSCs
[16–18], suggesting a need for effective osteogenic induction.
As a trace element in natural human bone tissue, strontium
pronouncedly enhances bone regeneration, mainly through
stimulating the osteogenic differentiation of BM-MSCs while
inhibiting the differentiation of osteoclasts [19]. In this study,
we found that strontium facilitated the proliferation and
osteogenic differentiation of PDB-MSCs, which shared a
great similarity to the response of BM-MSCs. As far as we
know, this is the first study to investigate the effect of stron-
tium on the proliferation and osteogenic differentiation of
PDB-MSCs in vitro.
According to our results, strontium exerted a dose-
dependent effect on the proliferation of human PDB-MSCs,
which was also observed in human BM-MSCs. Similarly, in
other MSC cultures, such as rat BM-MSCs [26] and human
adipose tissue-derived MSCs [37], strontium also exerted a
dose-dependent effect on their proliferation. In this study,
we found that 20mM strontium inhibited the replication of
both PDB- and BM-MSCs, while 1mM, 5mM, and 10mM
strontium promoted their proliferation. In the literature, dif-
ferent results have been reported regarding the cytotoxic
effect of strontium on human BM-MSCs [29–31] and osteo-
blasts [38, 39]. For instance, it was found that strontium at
concentrations of 1mM and above drastically decreased the
viability of human BM-MSCs [30]. However, 1mM stron-
tium was also reported to enhance the proliferation of human
BM-MSCs by another research group [31]; additionally, it
was determined that 210.7μg/mL strontium (i.e., 2.4mM)
did not inhibit the proliferation of human BM-MSCs [29].
These discrepancies associated with strontium cytotoxicity
may be partially due to the following reasons: First, human
BM-MSCs derived from different donors respond differently
to strontium stimulation [31]. Second, the experiment
conditions, including cell culture medium, cell passage, and
methods used to test cytotoxicity, varied greatly among
studies [29–31]. Considering this, it is difficult to compare
them directly; instead, the discrepancies described above
highlight the need to determine proper concentrations for
experiment cells.
Unlike a proproliferation effect of the high concentra-
tions of strontium (1mM, 5mM, and 10mM) on both BM-
and PDB-MSCs, they responded differently to some lower
concentrations of strontium. For instance, 0.01mM and
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Figure 4: Effect of strontium on the osteogenic differentiation of BM- and PDB-MSCs cultured in the growth medium. (a) Results of the ALP
staining of BM- and PDB-MSCs cultured with strontium for 7 days. Red indicates positive staining. Scale bar: 100 μm. (b) The ALP activity of
BM- and PDB-MSCs treated with strontium for 7 days, n = 4 for each group. (c) The osteogenic gene expression of BM- and PDB-MSCs on
days 3, 7, and 14, n = 4 for each group. All of these results are representative of three independent experiments. ∗P < 0:05when compared with
the GM group; #P < 0:01 when compared with the GM group. GM: growth medium.
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0.5mM strontium increased the growth kinetics of human
BM-MSCs but not that of PDB-MSCs. This cell-type-
specific effect of strontium on the replication of somatic cells
was also observed by other researchers [40], yet the mecha-
nism underlying different cell responses remains largely
unknown and needs further studies.
Regarding the osteogenic effects of strontium onMSCs, it
has been reported that proper concentrations of strontium
facilitated the osteogenic differentiation of rodent BM-
MSCs [26–28], as well as MSCs derived from human tissues,
such as bone marrow [29–31], umbilical cord [32], and
adipose tissue [41]. In this study, we investigated, for the first
time, the osteogenic effects of strontium on human PDB-
MSCs, and found that 10mM strontium, but not 0.1mM or
1mM strontium, promoted their osteogenic differentiation,
which will provide a simple approach to stimulate the osteo-
genic potential of PDB-MSCs for bone regeneration.
Nevertheless, we should acknowledge that there are some
limitations in this work. First, a pool of MSCs derived from
four donors, but not cell replicates from each donor, was used
in the experiments. Although this makes the comparison of
MSCs derived from two different tissues simple and straight-
forward, it fails to uncover the donor-dependent variation in
the responses of each cell type, which is important for future
clinical applications. Second, the cells used in this study were
at the middle passages. It is well-known that MSC-based
therapies need a large number of cells, and that MSCs at
passage 3-7 are usually used as graft cells in clinics [42];
therefore, we used both cell types at passage 5-7 in this study,
which were relevant to the clinics. However, it should be
noted that the differentiation potential of human MSCs
declines with increasing passage number [43], and conse-
quently, further studies are suggested to determine the
proper cell passage for strontium stimulation. Last but not
least, the mechanism underlining the osteogenic effects of
strontium on human PDB-MSCs remains unknown. It has
been reported that strontium enhanced the osteogenic differ-
entiation of MSCs through different cell signaling pathways,
such as the Ras/MAPK pathway [28], the Wnt/β-catenin
pathway [32], and the MAPK/ERK pathway [44]. However,
it is still unknown whether these signaling pathways are
involved in the osteogenic differentiation of PDB-MSCs
treated with strontium, and thus further studies are required
to understand the target pathway.
Based on the above studies, it is clearly demonstrated that
10mM strontium, rather than 0.1mM and 1mM strontium,
obviously facilitated the proliferation and osteogenic lineage
commitment of human PDB- and BM-MSCs. Considering
the dose-dependent effect of strontium on the proliferation
and differentiation of humanMSCs, it is noteworthy to deter-
mine the proper ion release profile of strontium-containing
bone scaffolds when using these MSCs to fabricate tissue
engineered bone grafts.
5. Conclusions
In conclusion, strontium promoted the proliferation and
osteogenic differentiation of human PDB- and BM-MSCs
in a dose-dependent manner. At low doses of strontium
(0.1mM and 1mM), the osteogenic gene expression of
PDB-MSCs was slightly different from that of BM-MSCs,
but the mineralization of both cell types was not enhanced.
By contrast, they shared a great similarity in the response to
a relative high dose of strontium (10mM), which promoted
their proliferation and osteogenic differentiation. This dose-
dependent effect of strontium should be taken into consider-
















Figure 5: Effect of strontium on the osteogenic differentiation of BM- and PDB-MSCs cultured in the osteogenic medium. (a) ALP staining
of BM- and PDB-MSCs cultured with strontium for 7 days. Red indicates positive staining. Scale bar: 100 μm. (b) ALP activity of BM- and
PDB-MSCs treated with strontium for 7 days. n = 4 for each group. (c) Osteogenic gene expression of BM- and PDB-MSCs on days 3, 7, and
14. n = 4 for each group. (d) Alizarin red staining of BM- and PDB-MSCs after 21 days of culture. Red indicates the mineralization of the
extracellular matrix. All of these results are representative of three independent experiments. ∗P < 0:05 when compared with the OST group;
#P < 0:01 when compared with the OST group. OST: osteogenic medium.
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PDB-MSCs: Placental decidual basalis-derived mesenchy-
mal stromal cells
Runx2: Runt-related transcription factor 2.
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